Pharmaceutical company Ephar has obtained registration for its Cannabidiol in two concentrations, 50 mg/mL and 100 mg/mL, which will be marketed in a low THC content drop solution.

Despite technical feasibility, Anvisa conditions the production of cannabidiol on the publication of a specific regulation, with validity in 90 days

Proposal aims to regulate the performance of non-profit entities in a controlled experimental environment, using the Regulatory Sandbox model to comply with STJ decision

How the pharmaceutical industry ensures quality and safety in cannabis-based products sold in Brazil

Gustavo Palhares believes that regulatory revision can relax prescriptions, expand access, and raise technical requirements in the medicinal cannabis sector

Projections indicate accelerated growth of the medicinal cannabis market by 2034, driven by regulatory changes and expanded therapeutic applications

The sector reached growth of over 65% in 2024; the medical cannabis market reached R$ 345 million in pharmacies

Agency defines a modular strategy for cannabis cultivation, establishing distinct rules for patient associations, research, and industry

Lecture led by specialist will address scientific updates, clinical use, and regulation of cannabinoid therapies in Dentistry during the event in São Paulo

Traveling at year-end and using medical cannabis? Learn what documents are required, how to transport the medication, and what precautions to take in Brazil and abroad.

The pharmaceutical company Farmausa Life Science has obtained registration for its Cannabidiol in two concentrations, 20 mg/mL and 100 mg/mL, with low THC content

Cannten's extract with 71.33 mg/mL expands medicinal treatment options in the country and receives authorization for commercialization

Extract from the company Endogen expands the portfolio of options for medicinal treatments and already has sanitary authorization for commercialization

Live broadcast will be held on the Agency's YouTube channel; board will have a strategic role in topics such as cannabis regulation in Brazil

The President emphasized the responsibility of the appointees and reinforced the importance of the agencies for the country's development

The event brings together experts, companies, and authorities to discuss regulatory advances, research, and innovation in cannabis-based therapies, connecting the entire public and private sector

With applications ranging from the pharmaceutical industry to construction, the sector is being structured with machinery, research, and investments, and is expected to grow even before the definitive regulation of cultivation in Brazil; the consultant discussed the topic during an interview at Andav 2025

Event will address rules that directly impact the herbal medicine sector and cannabis-based products; participation is open to the public.

The twelfth product approved by Anvisa, which will start being distributed at the end of May, is Zion Medpharma's Cannabis sativa Extract

According to the judge, the Judiciary and Legislature should not intervene in technical issues